These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32454797)

  • 41. Epidemiological study on more accurate diagnosis of prostate cancer.
    Kopecký J; Navláčilová V; Janoutová J; Janout V
    Cent Eur J Public Health; 2020 Mar; 28(1):65-69. PubMed ID: 32228820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
    Parekh DJ; Punnen S; Sjoberg DD; Asroff SW; Bailen JL; Cochran JS; Concepcion R; David RD; Deck KB; Dumbadze I; Gambla M; Grable MS; Henderson RJ; Karsh L; Krisch EB; Langford TD; Lin DW; McGee SM; Munoz JJ; Pieczonka CM; Rieger-Christ K; Saltzstein DR; Scott JW; Shore ND; Sieber PR; Waldmann TM; Wolk FN; Zappala SM
    Eur Urol; 2015 Sep; 68(3):464-70. PubMed ID: 25454615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
    Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
    Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.
    Abrate A; Lughezzani G; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Buffi N; Guazzoni G; Lazzeri M
    Korean J Urol; 2014 Jul; 55(7):436-45. PubMed ID: 25045441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic and predictive biomarkers in prostate cancer.
    Kontos CK; Adamopoulos PG; Scorilas A
    Expert Rev Mol Diagn; 2015; 15(12):1567-76. PubMed ID: 26548550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
    Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4-10 ng/mL.
    Hsieh PF; Chang CH; Yang CR; Huang CP; Chen WC; Yeh CC; Chou EC; Chen KL; Lien CS; Chen GH; Hsiao PJ; Chang YH; Wu HC
    Kaohsiung J Med Sci; 2018 Aug; 34(8):461-466. PubMed ID: 30041764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetic risk score improves prostate cancer risk assessment.
    Van Neste L; Groskopf J; Grizzle WE; Adams GW; DeGuenther MS; Kolettis PN; Bryant JE; Kearney GP; Kearney MC; Van Criekinge W; Gaston SM
    Prostate; 2017 Sep; 77(12):1259-1264. PubMed ID: 28762545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.
    Logozzi M; Angelini DF; Iessi E; Mizzoni D; Di Raimo R; Federici C; Lugini L; Borsellino G; Gentilucci A; Pierella F; Marzio V; Sciarra A; Battistini L; Fais S
    Cancer Lett; 2017 Sep; 403():318-329. PubMed ID: 28694142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.
    Ng CF; Chiu PK; Lam NY; Lam HC; Lee KW; Hou SS
    Int Urol Nephrol; 2014 Apr; 46(4):711-7. PubMed ID: 24136184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Screening for prostate cancer: moving forward in the molecular era.
    Vlachaki A; Baltogiannis D; Batistatou A; Tsambalas S; V Simos Y; E Palatianou M; Vezyraki P; Ragos V; Tsiambas E; Giannakopoulos X; Peschos D
    J BUON; 2018; 23(5):1242-1248. PubMed ID: 30570843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
    Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
    Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
    Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
    Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
    Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
    Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.
    Chiu PK; Lam TY; Ng CF; Teoh JY; Cho CC; Hung HY; Hong C; Roobol MJ; Chu WC; Wong SY; Sung JJ
    Asian J Androl; 2023 Nov; 25(6):674-679. PubMed ID: 37534902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.